Analysts Offer Insights on Healthcare Companies: Celgene (NASDAQ: CELG) and St. Jude Medical (NYSE: STJ)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Celgene (NASDAQ: CELG) and St. Jude Medical (NYSE: STJ).

Celgene (NASDAQ: CELG)

Canaccord Genuity analyst John Newman reiterated a Buy rating on Celgene (NASDAQ: CELG) today and set a price target of $156. The company’s shares opened today at $100.35.

According to TipRanks.com, Newman is ranked 0 out of 5 stars with an average return of -11.5% and a 34.7% success rate. Newman covers the Healthcare sector, focusing on stocks such as Advanced Accelerator Applications, Hutchison China MediTech Ltd, and Dimension Therapeutics Inc.

Currently, the analyst consensus on Celgene is Strong Buy and the average price target is $137.50, representing a 37.0% upside.

In a report issued on October 7, Jefferies also reiterated a Buy rating on the stock with a $134 price target.
St. Jude Medical (NYSE: STJ)

In a report released today, Jason Mills from Canaccord Genuity reiterated a Hold rating on St. Jude Medical (NYSE: STJ), with a price target of $85. The company’s shares opened today at $77.66.

Mills wrote:

“Date and time of first dissemination: October 18, 2016, 10:29 ET Date and time of production: October 18, 2016, 10:29 ET Target Price / Valuation Methodology: St.”

According to TipRanks.com, Mills is a 4-star analyst with an average return of 3.3% and a 57.2% success rate. Mills covers the Healthcare sector, focusing on stocks such as Integer Holdings Corporation, Tactile Systems Technology, and Trivascular Technologies.

St. Jude Medical has an analyst consensus of Hold, with a price target consensus of $79.17.